Tag Archives: healthcare

Drug discovery CRO MercachemSyncom adds biology services through acquisition

GIlde Healthcare

Utrecht (the Netherlands) – Gilde Healthcare portfolio company MercachemSyncom, the leading mid-sized European drug-discovery contract research organization, today announced that it has acquired Admescope Ltd., a provider of ADME-Tox services, based in Oulu (Finland) and Södertälje (Sweden). The acquisition of Admescope allows MercachemSyncom to significantly expand its service offering with tailor-made-in-vitro ADME-tox studies for pre-clinical and early clinical R&D projects. MercachemSyncom expects seamless integration with its existing medicinal, synthetic and development chemistry capabilities.

Admescope, founded in 2011, brings world-class expertise in drug metabolism, drug interactions, pharmacokinetics and quantitative bioanalysis. Its experienced scientific and management teams have executed ADME-Tox studies for pharma and biotech clients across the world.

Eelco Ebbers, CEO of MercachemSyncom, commented,

“We are pleased to welcome our new colleagues fom Admescope. The high quality, innovative and client-centric ADME-Tox services of Admescope represent a perfect, complimentary match with our organization. The addition of Admescope to MercachemSyncom marks an exciting year for our company. The expansion of our cGMP manufacturing apabilities via the acquisition of our Weert site at the beginning of the year has had an extremely positive effect on our business and client base, resulting in a record year in terms of medicinal and synthetic chemistry services.”

Rafael Natanek, Partner at Gilde Healthcare, commented,

“This is the third acquisition since our investment in MercachemSyncom, executing our active buy-and-build agenda to complement the strong organic growth of the company. Admescope adds specialized biology services to MercachemSyncom and enables integrated contract research services from hit-finding to Phase 2a. Combined with the acquisition of Alcami Weert last year, Admescope further solidifies MercachemSyncom’s position as the premier mid-sized drug discovery CRO in Europe.”

About MercachemSyncom

MercachemSyncom is the leading mid-sized European contract research organization offering innovative chemistry, medicinal chemistry, ADME-Tox, early drug substance development, and GMP production services to accelerate the drug discovery and development process in a flexible and cost-effective way. MercachemSyncom offers integrated drug-discovery services from hit to clinic. Working for many pharmaceutical and biotech companies throughout the world, MercachemSyncom is recognized for its high-quality products and services and its unprecedented problem-solving capabilities. For more information, visit the company’s website at www.mercachemsyncom.com.

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.

Categories: News

Tags:

Bridgepoint Growth to partner with Swedish medical dermatology group Diagnostiskt Centrum Hud

Bridgepoint

Diagnostiskt Centrum Hud (‘DCH’), the leading provider of medical dermatology services in Sweden, has partnered with Bridgepoint Growth to further support the company’s expansion.

Headquartered in Stockholm, DCH was founded in 2012 by its CEO and three dermatologists, combining their business and medical backgrounds to address the untapped demand for high quality medical dermatology treatments. The market is underpinned by structural growth drivers, including an aging population and an increase in the incidence of skin diseases such as skin cancer. s. DCH focuses on treating melanoma, psoriasis and other severe dermatology conditions.

Today DCH operates six clinics across four Swedish cities and is the clear market leader in Sweden. DCH is a high-quality platform well placed for future growth in the fragmented dermatology markets across Northern Europe.

“We are excited to partner with Bridgepoint in the next stage of our expansion and further build the best dermatology provider across the Nordics together with our colleagues,“ said Philip Jerlmyr, CEO DCH.

”We are very impressed by DCH’s successful expansion to-date creating the leading dermatology provider focused on clinical excellence and high customer satisfaction thanks to its having the best dermatologists. We look forward to supporting the DCH team in its next phase of expansion” added Ann Dahlman, partner at Bridgepoint Growth responsible for its investment activities in the Nordic region.

Advisors involved in the transaction were:

For Bridgepoint: Vinge (legal), KPMG (financial and tax), Roland Berger (commercial)

For management: AG Advokat (legal), GT (financial and tax)

Categories: News

Tags:

HealthComp Announces Partnership with New Mountain Capital

New Mountain Capital

Investment Firm to Support Leading Independent Third-Party Administrator’s Client Offerings and Growth 

FRESNO, Calif. and NEW YORK – November 9, 2020 – HealthComp Holding Company LLC (“HealthComp” or “the Company”), a leading independent Third Party Administrator (TPA) of healthcare benefits for self-funded employers, announced today that the Company has partnered with New Mountain Capital, a leading growth-oriented investment firm with $28 billion in assets under management.

Founded in 1994 and headquartered in Fresno, California, HealthComp is the largest independent Third-Party Administrator (TPA) of healthcare benefits in the U.S., serving more than 400,000 members in the self-funded employer industry. The Company offers best in class technology for healthcare benefits administration, payment integrity and care management services to address the “dual mandate” in the U.S. healthcare system: reducing costs and improving clinical outcomes and experience for employees. As part of the transaction, HealthComp’s CEO and management team will remain in place and invested in the company.

“HealthComp is dedicated to transforming benefits management into an experience that employees and employers love, and we are excited to partner with New Mountain Capital to recognize our full potential as a market leader,” said HealthComp CEO Jose Rivero. “We expect to benefit from the team’s deep sector knowledge, growth-oriented philosophy, and highly relevant industry relationships, to set the stage for our continued growth acceleration. We thank Alpine Investors for their fantastic partnership, and we look forward to continuing to build the HealthComp platform with the support and strategic guidance of New Mountain Capital.”

“HealthComp’s strong track record of cost containment and unwavering commitment to improving clinical outcomes for employee populations creates the opportunity to build a leading, scaled platform in an attractive, growing market with significant upside potential,” said Matt Holt, Managing Director and President, Private Equity at New Mountain Capital. “New Mountain Capital’s deep experience in healthcare cost containment will allow HealthComp to capitalize on an unparalleled opportunity to leverage institutional knowledge to drive business building and increase value for customers.”

Kyle Peterson, Managing Director at New Mountain Capital, said, “HealthComp’s scale, track-record, and market reputation make it the ideal platform for the development of a next generation TPA model. We see significant opportunity to leverage New Mountain’s capabilities in data and analytics to drive core platform competencies and a unique commercial strategy. Further investment in an already robust technology platform with the expansion of cost and clinical management capabilities will drive best-in-class cost containment and employee experience for self-funded employers and their employees.”

TripleTree LLC served as exclusive financial advisor and Wilson Sonsini served as legal counsel to HealthComp in the transaction. Ropes & Gray LLP provided legal counsel to New Mountain.

About HealthComp 

For more than 25 years, HealthComp has been dedicated to transforming benefits administration. Bringing together concierge-level service, operational excellence, powerful analytics and cost management, HealthComp has built a solution that integrates seamlessly with any benefits ecosystem. HealthComp has offices in California, Illinois, West Virginia and Pennsylvania. Visit healthcomp.com.

About New Mountain Capital 

New Mountain Capital is a New York-based investment firm that emphasizes business building and growth, rather than debt, as it pursues long-term capital appreciation. The firm currently manages private equity, public equity, and credit funds with $28 billion in assets under management. New Mountain seeks out what it believes to be the highest quality growth leaders in carefully selected industry sectors and then works intensively with management to build the value of these companies. For more information on New Mountain Capital, please visit www.newmountaincapital.com 

Press Release Contacts

HealthComp 

Joy Scott
Phone: 818.610.0270
joy@scottpublicrelations.com

New Mountain Capital 

Dana Gorman / Claire Walsh
Abernathy MacGregor
(212) 371-5999
dtg@abmac.com / cw@abmac.com

Categories: News

Tags:

Alpine’s HealthComp Announces Partnership With New Mountain Capital

Alpine

SAN FRANCISCO–(BUSINESS WIRE)–Alpine Investors (“Alpine”), a middle-market private equity firm that focuses on investing in people to build enduring companies, today announced that HealthComp Holding Company, LLC (“HealthComp”), a leading independent Third Party Administrator (TPA), is partnering with New Mountain Capital, a leading growth-oriented investment firm with $28 billion in assets under management. As part of the transaction, Alpine is exiting its investment in HealthComp.

Founded in 1994 and headquartered in Fresno, California, HealthComp is the largest independent Third-Party Administrator (TPA) of healthcare benefits in the U.S., serving more than 400,000 members in the self-funded employer industry. The Company offers best in class technology for healthcare benefits administration, payment integrity and care management services to address the “dual mandate” in the U.S. healthcare system: reducing costs and improving clinical outcomes and experience for employees. As part of the transaction, HealthComp’s CEO and management team will remain in place and invested in the company.

“Through our partnership with Alpine, HealthComp has been able to address the ‘dual mandate’ in U.S. healthcare of reducing costs and improving the member experience,” said Jose Rivero, CEO at HealthComp. “We thank Alpine Investors for their fantastic partnership, and we look forward to continuing to build the HealthComp platform with the support and strategic guidance of New Mountain Capital.”

“We are proud of what we have accomplished with HealthComp over the past four years. Jose’s people-driven leadership, innovation, and focus on operational excellence have created the leading independent TPA in the country. We’re excited to see HealthComp’s growth continue as a result of its partnership with New Mountain Capital,” said Will Adams, Partner at Alpine Investors.

TripleTree, LLC served as the exclusive financial advisor to HealthComp for the transaction and Wilson Sonsini Goodrich & Rosati served as legal counsel.

About Alpine Investors

Alpine Investors is a people-driven private equity firm that is committed to building enduring companies by working with, learning from, and developing exceptional people. Alpine specializes in investments in middle-market companies in the software and services industries. Its PeopleFirst™ strategy includes a CEO-in-Residence program which allows Alpine to bring proven leadership to situations where additional or new management is needed post-transaction. Alpine is currently investing out of its $1 billion seventh fund. For more information, visit http://www.alpineinvestors.com.

About HealthComp Holding Company, LLC

For more than 25 years, HealthComp has been dedicated to transforming benefits administration. Bringing together concierge-level service, operational excellence, powerful analytics and cost management, HealthComp has built a solution that integrates seamlessly with any benefits ecosystem. HealthComp has offices in California, Illinois, West Virginia and Pennsylvania. For more information, visit healthcomp.com.

Categories: News

Tags:

Huntsworth to Acquire Nucleus Global

Clayton Dubilier Rice

Establishes a Global Leader in Medical Communications

Friday, November 6, 2020
London and New York

Huntsworth, a Clayton, Dubilier & Rice portfolio company, has announced an agreement to acquire Nucleus Global from its founder, Stephen Cameron.

The combination will create a global leader in the fast growing medical communications space and further establish Huntsworth as a leading Pharma Commercialization platform, offering a suite of medical affairs, market access, and marketing services to large and mid-size pharmaceutical and biotech companies across the life cycle of drugs.

With a 30-year history of organic growth, Nucleus has become one of the largest privately owned medical communications groups with 14 offices around the world and more than 800 experts serving the biggest healthcare and medical assets in the world. Nucleus Founder and Chair, Stephen Cameron will join the main Board of Huntsworth and continue to lead Nucleus.

“This is a transformational milestone for two highly complementary businesses,” said Eric Rouzier, CD&R Partner. “We believe the combined businesses will offer a highly differentiated and complementary suite of high science solutions to support its clients in the pharmaceutical industry in developing and commercializing drugs globally. We are delighted that Stephen will remain with the business through the next phase of its growth.”

CD&R, which acquired Huntsworth in May, has a long track record investing in healthcare businesses globally. Huntsworth Chairman Liam FitzGerald, Operating Advisor to CD&R funds and former CEO of UDG Healthcare, will continue in the Chairman role for the new combined business upon close of the transaction, expected in December 2020.

About Nucleus
Nucleus Global is a medical communications group, which provides communications strategy, publications planning, expert and patient engagement, scientific events management, medical education, internal communications, training and clinical support for pharmacy and biotech companies.  Nucleus has its headquarters in London and operates dedicated, conflict-free teams across 14 offices and 800 employees in the US, Europe and Asia-Pacific. For more information, please visit www.nucleus-global.com/. 

About Huntsworth
Huntsworth is an international healthcare and communications group. The Group’s principal area of focus is Health, which provides medical affairs and marketing services to large and mid-size pharmaceutical and biotech companies. It also has a smaller Communications group, which provides a wide range of communications and advisory services including strategic communications, public affairs, investor relations and consumer marketing. Huntsworth is headquartered in London and operates 46 offices around 20 countries with approximately 2,000 employees. For more information, please visit www.huntsworth.com/.

About Clayton, Dubilier & Rice
Founded in 1978, Clayton, Dubilier & Rice is a private investment firm with a strategy predicated on enhancing the value of portfolio businesses by supporting long-term growth, productivity, capital efficiency, and related strategic measures. Since inception, CD&R has managed the investment of more than $30 billion in 95 companies with an aggregate transaction value of more than $150 billion. The Firm has offices in New York and London. For more information, visit www.cdr-inc.com.

Categories: News

Tags:

Unified Women’s Healthcare Announces New Investment from Altas Partners

Altas Partners

November 5, 2020

Unified Women’s Healthcare Announces New Investment from Altas Partners and Ares Management to Accelerate Mission of Empowering Physicians to Transform Women’s Healthcare

Unified Women’s Healthcare (“Unified” or the “Company”), the leading practice management platform in women’s healthcare, today announced that it has entered into a definitive agreement to add Altas Partners (“Altas”) as a strategic partner. Altas, a long-term oriented investment firm, will become Unified’s largest investor, while Ares Management Corporation (“Ares”), in equal partnership with Altas, will continue to be a significant investor in the Company. As part of the transaction, private equity funds managed by Ares will make a significant new investment in the Company. The investments from Altas and Ares, alongside the physicians who are Unified’s partners, will enable the Company to expand the breadth of services it provides to its affiliated practices, provide capital for growth, and allow the Company to further invest in market-leading value-based care capabilities for providers and payers.

Founded in 2009, Unified’s mission is to empower physicians to positively impact and lead the effort to transform women’s healthcare for the benefit of their patients. Its strategic focus remains on the preservation of clinical autonomy and decision-making at the practice level, while advancing the impact of private practice through value-based care transformation. In addition to offering professional management expertise and innovative technology, Unified seeks to grow its affiliated practices through ancillary services and platform acquisitions. Today, Unified supports more than 1,800 providers in 12 states and the District of Columbia, who collectively care for more than 2 million women each year.

“We are thrilled to welcome Altas as our partner, and alongside Ares and our physician-owners, their collective investment is a testament to the strength of our affiliated practices and the national platform we have built,” said Bob LaGalia, President and Chief Executive Officer of Unified. “Altas and Ares both understand and support our core mission, which is to continue to support outstanding physicians as they improve women’s healthcare. This investment will allow Unified to continue to support our affiliated practices as they attract great physicians, provide best-in-class capabilities, and further our investments in value-based care.”

The transaction is expected to close in December 2020, subject to customary closing conditions and regulatory approvals.

About Unified Women’s Healthcare

Founded in 2009, Unified Women’s Healthcare is the largest Ob-Gyn physician practice management company supporting more than 1,800 providers across 12 states and the District of Columbia. Unified remains an indispensable source of business knowledge, innovation, and support to empower physicians to make the greatest impact on transforming women’s healthcare for their patients. For more information, visit www.unifiedwomenshealthcare.com.

About Altas Partners

Founded in 2012, Altas Partners is an investment firm with a long-term orientation focused on acquiring significant interests in high-quality, market-leading businesses in partnership with outstanding management teams. The firm manages approximately US$7 billion on behalf of endowments, foundations, family offices, public pension funds, and other institutional investors. The firm’s past and present portfolio companies include DuBois Chemicals, University of St. Augustine for Health Sciences, Tecta America, Hub International, PADI, Medforth Global Healthcare Education, Capital Vision Services (MyEyeDr.), and NSC Minerals. For more information, please visit www.altas.com.

About Ares Management Corporation

Ares Management Corporation is a leading global alternative investment manager operating integrated businesses across Credit, Private Equity, Real Estate and Strategic Initiatives. Ares Management’s investment groups collaborate to deliver innovative investment solutions and consistent and attractive investment returns for fund investors throughout market cycles. Ares Management’s global platform had approximately $179 billion of assets under management as of September 30, 2020 with more than 1,400 employees operating across North America, Europe and Asia Pacific. For more information, please visit www.aresmgmt.com.

Categories: News

Tags:

Successful exit for Innovestor Ventures – Synoste gets acquired by Globus Medical

Innovestor

Innovestor Ventures exists Synoste, a Finnish startup that has developed high technology implants for minimally invasive bone lengthening treatment. In addition to Innovestor, Synoste had received investment from High-Tech Gruenderfonds (HTGF), Evonik Venture Capital, Lifeline Ventures, AOL Foundation and angels. Globus Medical acquired Synoste in Q2/2020 for $23.5 million. 

Kickstarting the third generation Limb Lengthening system, Synoste’s unique implants lengthen the bone gradually over a period of months, offering improved outcomes and experiences for patients and surgeons alike.   

Synoste was founded by Harri Hallila, Antti Ritvanen and Juha Haaja, with a shared vision and the know-how needed to bring about third generation limb lengthening systems.  

 “It has been a pleasure working and watching such a driven and ambitious team progress and grow throughout the ups and downs that startups face. Synoste has chosen a great partner in Globus Medical to continue their journey enabling them to take their technology to the next global level” commented Innovestor Venture’s Partner Petri Laine.  

Globus Medical is a leading medical device manufacturer based in Pennsylvania, USA that develops, manufactures, and distributes musculoskeletal device solutions.  

 

For more information  

Petri Laine

Partner, Innovestor Ventures

petri.laine(a)innovestor.fi

+358 400 909 447

Categories: News

Tags:

Klinikk for Alle and Naprapatlandslaget create the dominant player within physical manual therapy

Litorina

  • Klinikk for Alle (“KFA”) acquires Naprapatlandslaget and further strengthens the position as the clear market leading player within physical manual therapy in the Nordics
  • Both companies share a strong focus on quality care to patients and aim to always attract the best therapists, and have a proven ability to grow organically in existing clinics and with new greenfields, as well as through strategic acquisitions
  • The merger of KFA and Naprapatlandslaget builds on a clear industrial logic in which the companies are bringing complementary skills and resources to accelerate further growth and achieve operational excellence
  • The combined group will initially have around 400 therapists and 62 clinics, supported by central strategic functions, forming a solid platform for continued expansion in existing markets as well as internationally
  • The current owners of Naprapatlandslaget re-invest significantly in the combined group company, Physical Medicine Group, in which Litorina remains the majority owner
KFA NPL

Litorina invested in Klinikk for Alle in January this year, with an aim to build the dominant European player within physical medicine. With the acquisition of Naprapatlandslaget, a large step is taken on this journey, adding a new market (Sweden), naprapathy to the service offering, and almost 100 skilled therapists and 31 clinics in both Sweden and Norway. The combined group, with around 400 therapists across 62 clinics, forms a solid platform for operational excellence and continued growth in existing markets as well as internationally.

“The merger of KFA and Naprapatlandslaget further strengthens our leading position within physical manual therapy in the Nordics, with strong focus on delivering quality treatments to our patients as well as being in the forefront within our fields of profession. Our patients will now benefit from having both improved availability with increased number of clinics and a broader service offering, always at our high treatment and service standard. Moreover, we now have an even stronger platform to grow from going forward. The management teams of KFA and Naprapatlandslaget are very excited to embark on this journey together”, says Oscar Maaseide, Group CEO of Physical Medicine Group.

For further information, please contact:
Oscar Maaseide, +47 900 43 250, Group CEO Physical Medicine Group
Jesper Ask, +47 924 49 057, CEO Naprapatlandslaget / Country Manager Norway, Physical Medicine Group
Gustav Thott, +46 708 55 66 30, Partner, Litorina V Advisor

Klinikk for Alle, founded in 1989, is the market leading manual physical therapy provider in Norway. The company currently operates 31 clinics, with more to open during 2020, and has around 300 therapists performing ca. 425,000 treatments per year. For more information, please visit www.klinikkforalle.no.

Naprapatlandslaget, founded in 2002, is the market leading provider of naprapathy treatments in the Nordics. Today, the company has around 100 therapists across 31 clinics in Norway and Sweden. For more information, please visit www.naprapatlandslaget.se / www.naprapatlandslaget.no.

Litorina, founded in 1998, invests in niche market leading companies with headquarters in the Nordics. Litorina partners with management teams and entrepreneurs that want to take their companies to full potential. Litorina aims to build bigger and better companies by contributing relevant experience and knowledge, resources for expansion and a lot of passion. For more information, please visit www.litorina.se.

Categories: News

Tags:

Hoosier Foot & Ankle Joins Upperline Health

Upperline Health, leader in lower-extremity care, has partnered with Hoosier Foot & Ankle, a 9 physician and 11 clinic group serving the greater Indianapolis area. Patrick DeHeer, DPM and 8 associates will be joining the Upperline Health team through the partnership.

“Hoosier Foot & Ankle is a huge partnership for Upperline Health in Indiana,” said Michael King, DPM, Chief Medical Officer at Upperline Health. “Our rapid growth in the Indianapolis area and partnership with these top-notch foot and ankle specialists will allow Upperline Health to continue serving more patients in need across the country.”

“I have put my heart and soul into building Hoosier Foot & Ankle into something special over the past 16 years, and I am thrilled to be partnering with Upperline Health,” said DeHeer. “Upperline’s strategic plan and vision are exciting and market changing. Being part of such an innovative organization that puts patient outcomes first using data-driven care is game changing.”

In addition to Dr. DeHeer, Hoosier Foot & Ankle includes the following associate physicians: Farwa Abid-Hoffman, DPM, AACFAS; Christine Bhinder, DPM; Bryan Camp, DPM; Anthony Jagger, DPM; David Smith, DPM; Richard L. Thatcher, DPM; Tyler Vestile, DPM; and Aaron Warnock, DPM, AACFAS.

About Hoosier Foot & Ankle

As a premier podiatry clinic in the Greater Indianapolis area and Kokomo, the team at Hoosier Foot & Ankle offers comprehensive care and treatment all under one roof. The team’s practice philosophy is based upon providing superior, honest and cutting-edge professional care for each and every patient. The podiatrists are committed to offering the latest and most effective technologies and procedures available on the market. Learn More

About Upperline Health

Upperline Health provides the highest quality integrated extremity care to patients in need through a skilled and compassionate team. Upperline Health is building out a network of the top physicians and practices across the country while partnering with health plans and community providers to deliver care in a consistent and high-quality manner.

Upperline Health is one of the nation’s largest practices dedicated to lower extremity care with providers in Alabama, California, Florida, Indiana and Tennessee.

‍

Categories: News

Tags:

Salvia BioElectronics

Inkef Capital

Salvia BioElectronics receives FDA Breakthrough Device Designation for innovative neurostimulation solution

 Bioelectronics solution addresses drug-refractory chronic migraine

Eindhoven, the Netherlands, November 3, 2020 – Salvia BioElectronics B.V. (“Salvia”), a neurostimulation platform company targeting chronic migraine, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its implantable neurostimulation system to address chronic migraine.

Salvia is developing an innovative neurostimulation solution for chronic migraine based on a novel device concept with unique benefits to both patients and physicians. Migraine is the first cause of disability in under 50s, affecting one out of seven people, predominantly women[1]. People with migraine experience episodes of throbbing, pulsating pain, sometimes accompanied by nausea, vomiting, and sensitivity to light, that can last anywhere from a few hours to a few days. More than five percent of patients suffer from chronic migraine, where they experience migraines for an average of 22 days per month[2]. Migraine does not only impact wellbeing; it has an enormous impact on work, school, family and social lives.

Wim Pollet, Chief Medical Officer of Salvia BioElectronics, noted: “The FDA breakthrough device designation of our neurostimulation system reflects the recognition of the large unmet medical need of patients suffering from refractory chronic migraine, and the potential of Salvia’s bioelectronic foil technology to address this. We look forward to working closely with the FDA to expedite the review process to accelerate the development of our therapy.”

Patients with chronic migraine suffer from 15 or more headache days per month, with an average of 22 days per month, despite best medical treatment1. Only 1 in 3 of drug-refractory chronic patients are helped with the newest generation of anti-migraine drugs, leaving many patients in medical need.

While neurostimulation has been demonstrated to be effective for these patients, there are no approved devices commercially available. Salvia was founded with the mission to help these patients suffering from chronic migraine by developing thin and conforming bioelectronic foils that uniquely adapt to the anatomy of the head.

The FDA’s Breakthrough Devices Program has been established to help patients to have more timely access to medical devices that provide more effective treatment for irreversibly debilitating diseases or conditions. The designation allows Salvia to have more frequent interaction with the FDA regulatory experts when preparing its FDA submissions, followed by prioritized reviews.

 

Enquiries

For more information please contact:

Salvia BioElectronics

Daniel Schobben, Chief Operating Officer

mb.info@salvianeuro.com

 

Optimum Strategic Communications

Supriya Mathur, Elakiya Rangarajah

+44 (0) 20 3922 1906 / +44 (0) 203 922 0891

Salvia@optimumcomms.com

 

 About Salvia BioElectronics B.V.

Salvia BioElectronics is an innovative Dutch startup active in the emerging field of bioelectronics. Salvia BioElectronics was founded in 2017 by neuromodulation industry veterans with the ambition to develop a bioelectronics therapy for people suffering from chronic migraine that is as easy as taking medication yet side-effect free. Building on research around known neural targets in migraine, the startup is working to develop the right form factor for stimulation that is effective, safe, and affordable.

Migraine is the first cause of disability in under 50s, affecting one out of seven people, predominantly women. People with migraine experience episodes of throbbing, pulsating pain, sometimes accompanied by nausea, vomiting, and sensitivity to light, that can last anywhere from a few hours to a few days. More than five percent of patients experience migraines for 15+ days per month – with an average of 22 days – a condition described as chronic migraine. www.salvianeuro.com

[1]Steiner, T.J., Stovner, L.J., Vos, T. et al. Migraine is first cause of disability in under 50s: will health politicians now take notice?. J Headache Pain 19, 17 (2018). https://doi.org/10.1186/s10194-018-0846-2

[2]Richard B Lipton, Merle L Diamond, Stewart J Tepper, Expert Perspectives—Migraine Prevention for Highly Impacted Patients.

Categories: News

Tags: